This page shows the publications co-authored by Howard Weiner and Zongqi Xia.
Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. JAMA Netw Open. 2021 11 01; 4(11):e2134627.
Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Mult Scler Relat Disord. 2022 Jan; 57:103333.
Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Ann Neurol. 2016 Feb; 79(2):178-89.
Modeling disease severity in multiple sclerosis using electronic health records. PLoS One. 2013; 8(11):e78927.
A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One. 2010 Nov 30; 5(11):e14169.
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.